Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Salt – page 6

330 clinical trials in Salt, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Salt at a glance
330
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

330 trials in Salt

Open in trial search

Cervix carcinoma

Recruiting

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer

Recruiting

A Study of INCB123667 in Patients With Platinum-Resistant Ovarian Cancer That Has High Levels of Cyclin E1 Protein

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:INCB123667
  • Sponsor:Incyte Corp.

HER2 positive breast cancer

Recruiting

Study of Trastuzumab Deruxtecan and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Solti Group

Hepatocellular carcinoma

Recruiting

A Study of Atezolizumab and Bevacizumab Before and After Surgery in Patients with Liver Cancer at High Risk of Coming Back

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Cardiomyopathy

Recruiting

Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atenolol
  • Sponsor:Andrea Di Marco

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303
  • Sponsor:BioNTech SE

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Insel Gruppe AG

Endometrial cancer+2

Recruiting

Study of dostarlimab treatment before surgery in patients with stage II-III endometrial cancer with specific genetic markers

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Novartis Pharma AG

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Salt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing-remitting multiple sclerosis and its treatment approaches, including comparative studies of novel therapies and established medications.

  • Treatment Comparisons
  • Long-term Safety Studies
  • Disease Progression Management

Multiple innovative therapies are being evaluated to improve patient outcomes and reduce disease progression.

02 Progressive MS Studies

Dedicated research into Primary Progressive Multiple Sclerosis (PPMS), exploring new therapeutic options through targeted treatment approaches.

  • Disability Progression
  • Novel Treatment Mechanisms
  • Long-term Effectiveness

Studies focus on developing treatments to delay disability progression in PPMS patients.

03 Specialized Conditions

Research addressing specific medical conditions including severe primary hand hyperhidrosis and pregnancy-related conditions such as nausea and vomiting.

  • Topical Treatments
  • Pregnancy-related Conditions
  • Quality of Life Improvements

Clinical investigations aim to enhance treatment options and patient comfort across various conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.